We are live on ! Find out more
BC

Broadwood Capital Portfolio holdings

AUM $1.91B
1-Year Est. Return 44.39%
This Fund
S&P 500
This Quarter Est. Return
-27.35%
1 Year Est. Return
+44.39%
3 Year Est. Return
+110.36%
5 Year Est. Return
+52.4%
10 Year Est. Return
+1,142.23%
AUM
$713M
AUM Growth
-$364M
Cap. Flow
-$5.32M
Cap. Flow %
-0.75%
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
–
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
SER icon
Serina Therapeutics
SER
+$10.8M

Top Sells

Rank Stock Value
1
LCTX icon
Lineage Cell Therapeutics
LCTX
+$6.57M
2
MNST icon
Monster Beverage
MNST
+$5.13M
3
STAA icon
STAAR Surgical
STAA
+$4.46M

Sector Composition

Rank Sector Weight
1 Healthcare 55.12%
2 Consumer Staples 32.32%
3 Miscellaneous 7.89%
4 Industrials 4.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STAA icon
1
STAAR Surgical
STAA
$1.13B
$343M 48.1%
10,740,630
-114,549
-1% -$4.46M
MNST icon
2
Monster Beverage
MNST
$87.7B
$230M 32.32%
18,717,232
-377,600
-2% -$5.13M
IWM icon
3
iShares Russell 2000 ETF
IWM
$77.2B
$56.2M 7.89%
420,000
– –
AXON
4
Axon Enterprise
AXON
$38.3B
$33.3M 4.67%
760,062
– –
LCTX icon
5
Lineage Cell Therapeutics
LCTX
$263M
$27.4M 3.84%
29,971,561
-4,285,933
-13% -$6.57M
IMDX
6
Insight Molecular Diagnostics
IMDX
$125M
$10.4M 1.47%
378,247
– –
SER icon
7
Serina Therapeutics
SER
$58.2M
$8.96M 1.26%
+85,219
New +$10.8M
AST
8
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
$3.28M 0.46%
5,292,156
– –
DAL icon
9
PUT
Delta Air Lines
DAL
$51.5B
– –
-200,000
Closed -$11.6M
MNST icon
10
PUT
Monster Beverage
MNST
$87.7B
– –
-3,200,000
Closed -$46.6M

Similar funds

EWS
Evergreen Wealth Solutions Williamsport, Pennsylvania $1.91B AUM 19.99% 1-Year Est. Return
RMA
Roffman Miller Associates Philadelphia, Pennsylvania $1.91B AUM 28.29% 1-Year Est. Return
LWMT
Legacy Wealth Management (Tennessee) Memphis, Tennessee $1.91B AUM 17.42% 1-Year Est. Return
FIB
First Interstate Bank Billings, Montana $1.92B AUM 19.65% 1-Year Est. Return
SAM
Southeastern Asset Management Memphis, Tennessee $1.92B AUM 6.41% 1-Year Est. Return
HPC
Hill Path Capital New York $1.92B AUM 5.67% 1-Year Est. Return
R
Rebalance Palo Alto, California $1.91B AUM 16.23% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return

Broadwood Capital's Q4 2018 Portfolio in Review

As of Q4 2018, Broadwood Capital held 10 positions worth $713M, down 34% from $1.08B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Broadwood Capital's Q4 2018 filing shows 1 new, 3 reduced and 2 closed positions. Its largest new stake was Serina Therapeutics: 85,219 shares worth $8.96M. The largest sale was Lineage Cell Therapeutics, an estimated $6.57M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 57% a quarter earlier, followed by Consumer Staples and Miscellaneous.

  • Broadwood Capital's largest Q4 2018 buy was Serina Therapeutics: 85,219 shares worth $8.96M.
  • Broadwood Capital's biggest Q4 2018 reduction was Lineage Cell Therapeutics, cutting an estimated $6.57M.
  • Broadwood Capital's ten largest holdings make up 100% of its $713M portfolio in Q4 2018.
  • Broadwood Capital opened 1 new position and closed 2 in Q4 2018.
  • Broadwood Capital's portfolio value fell 34% quarter-over-quarter to $713M.

Based on Broadwood Capital's 13F filing for Q4 2018, filed 14 Feb 2019.